Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108797 · ClinicalTrials.gov registry record · Phase 4
Trial of NovoSeven® in Haemophilia - Joint Bleeds
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT00108797 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 42 participants.
The verdict
NCT00108797, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.
Interventions
- DRUG eptacog alfa (activated)
- DRUG Feiba VH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108797
The ClinicalTrials.gov registry entry for NCT00108797 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which eptacog alfa (activated) is the first listed.
NCT00108797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108797 about?
NCT00108797 is a clinical study titled "Trial of NovoSeven® in Haemophilia - Joint Bleeds". This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.
What is the current status of trial NCT00108797?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2001-09. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00108797?
The interventions under investigation include: eptacog alfa (activated) (DRUG), Feiba VH (DRUG).
Who is sponsoring clinical trial NCT00108797?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.